3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
7
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Refractory or Relapsed Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Non-metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
venetoclax
14
ibrutinib
11
Rituximab
9
obinutuzumab
8
Specimen Handling
7
Cyclophosphamide
7
acalabrutinib
6
Biopsy
6
zanubrutinib
5
pirtobrutinib
5
fludarabine phosphate
4
Lenalidomide
4
ARQ531
4
idelalisib
3
Whole-Body Irradiation
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
fludarabine
2
Vincristine
2
Sirolimus
2
Prednisone
2
Mycophenolic Acid
2
Doxorubicin
2
CT-P10
2
Bendamustine Hydrochloride
2
treosulfan
1
tocilizumab
1
pembrolizumab
1
mirdametinib
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
darolutamide
×
30 days
×
Clear all
No trials found.